Education
About Us
Working with TipRanks
Follow Us
IGC Pharma (IGC)
XASE:IGC
IGC Stock Chart & Stats
$0.30
>-$0.01(-2.38%)
At close: 4:00 PM EST
$0.30
>-$0.01(-2.38%)
Day’s Range― - ―
52-Week Range$0.24 - $0.50
Previous CloseN/A
Volume646.33K
Average Volume (3M)715.71K
Market Cap
$28.28M
Enterprise Value$26.44M
Total Cash (Recent Filing)$938.00K
Total Debt (Recent Filing)$142.00K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Jun 15, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding98,796,090
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.45
Price to Sales (P/S)17.16
P/FCF Ratio-4.13
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue22.05
Enterprise Value/Gross Profit65.94
Enterprise Value/Ebitda-3.48
Forecast
1Y Price Target
$5.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$1.05M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInterim Phase 2 data showed a statistically significant reduction in agitation versus placebo for the lead candidate, which could validate clinical benefit and support positive re‑rating of the stock.
Market Opportunity And Portfolio BreadthA portfolio that includes multiple novel Alzheimer’s candidates, with two programs at later stages, targets a large unmet market and could deliver substantial upside if programs progress successfully.
Pipeline Milestones And Product DevelopmentAdvancing enrollment in the Phase 2 CALMA trial with over half of participants enrolled and a planned trial completion in early 2026, together with a forthcoming AI beta program, creates visible upcoming milestones that may attract investor interest.
Bears Say
Clinical Development RiskSignificant development and clinical trial risks remain, so setbacks or negative outcomes in key studies could materially reduce the company’s valuation.
Commercialization UncertaintyLong and uncertain paths to regulatory approval and commercialization mean that even promising clinical results may not translate quickly into revenue, maintaining high stock volatility.
Financial VulnerabilityMinimal revenue as a clinical‑stage company increases reliance on external financing, raising the risk of shareholder dilution if additional capital is required.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.24 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $28.28M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Jun 15, 2026 which is in 84 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Mar 19, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.03.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 98,796,090 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -1.091%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
IGC Earnings Call
Q2 2025
0:00 / 0:00
IGC Stock 12 Month Forecast
Average Price Target
$5.00
▲(1566.67% Upside)
Technical Analysis
Ownership Overview
4.36% Insiders
1.39% Mutual Funds
0.23% Other Institutional Investors
93.30% Public Companies and
Individual Investors